Matches in SemOpenAlex for { <https://semopenalex.org/work/W3121073486> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W3121073486 endingPage "S790" @default.
- W3121073486 startingPage "S789" @default.
- W3121073486 abstract "Abstract Background Relebactam (REL) inhibits class A and C β-lactamases, including KPC, and was approved in the United States combined with imipenem (IMI) and cilastatin for complicated urinary tract and intraabdominal infections. We evaluated the activity of IMI/REL against non-Morganellaceae (NME) and P. aeruginosa collected as part of the global SMART surveillance program from patients with bloodstream infections (BSI) in the US and Canada. Methods In 2018, 24 US and 8 Canadian hospitals each collected up to 50 consecutive aerobic or facultative gram-negative pathogens from patients with BSI. MICs were determined using CLSI broth microdilution and interpreted with 2020 CLSI breakpoints. Multidrug-resistance (MDR) was defined as resistance to ≥3 of the following sentinel drugs: amikacin, aztreonam, cefepime, ceftazidime (NME only), ciprofloxacin, colistin, imipenem, and piperacillin/tazobactam. Results The 5 most common species among 1463 collected BSI isolates were E. coli (46.9%), K. pneumoniae (16.0%), P. aeruginosa (8.5%), P. mirabilis (4.8%), and E. cloacae (4.3%). Susceptibility to IMI/REL and comparators of selected species and subsets of resistant phenotypes is shown in the table. IMI/REL was active against 99.8% of NME isolates; only meropenem, ceftazidime/avibactam, and amikacin showed comparable activity. Per 2020 CLSI guidelines, Enterobacterales and P. aeruginosa isolates are no longer considered susceptible to colistin. IMI/REL maintained activity against 89-100% of NME isolates that were nonsusceptible (NS) to β-lactams or MDR. Among P. aeruginosa, IMI/REL was active against 94.4% of isolates; a susceptibility rate only exceeded by amikacin. The addition of relebactam lowered the MIC90 for P. aeruginosa from 16 µg/mL to 1 µg/mL. IMI/REL maintained activity against 40-77% of P. aeruginosa isolates NS to β-lactams or MDR; susceptibility rates only exceeded by amikacin. Susceptibility to IMI/REL was similar in the US (99.8% of NME [n=846]; 93.8% of P. aeruginosa [n=96]) and Canada (99.7% of NME [n=339]; 96.4% of P. aeruginosa [n=28]). Table Conclusion In the US and Canada, IMI/REL could provide an important treatment option for patients with BSI caused by resistant gram-negative organisms. Disclosures Sibylle Lob, PhD, IHMA (Employee)Pfizer, Inc. (Consultant) Katherine Young, MS, Merck & Co., Inc. (Employee, Shareholder)Merck & Co., Inc. (Employee, Shareholder) Mary Motyl, PhD, Merck & Co, Inc (Employee, Shareholder) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Consultant)Shionogi & Co., Ltd. (Independent Contractor)" @default.
- W3121073486 created "2021-01-18" @default.
- W3121073486 creator A5017159626 @default.
- W3121073486 creator A5038009031 @default.
- W3121073486 creator A5042149117 @default.
- W3121073486 creator A5062847775 @default.
- W3121073486 creator A5089366807 @default.
- W3121073486 date "2020-10-01" @default.
- W3121073486 modified "2023-10-16" @default.
- W3121073486 title "1584. In Vitro Activity of Imipenem/Relebactam against Gram-Negative Pathogens from Patients with Bloodstream Infections in the United States and Canada – SMART 2018" @default.
- W3121073486 doi "https://doi.org/10.1093/ofid/ofaa439.1764" @default.
- W3121073486 hasPublicationYear "2020" @default.
- W3121073486 type Work @default.
- W3121073486 sameAs 3121073486 @default.
- W3121073486 citedByCount "1" @default.
- W3121073486 countsByYear W31210734862021 @default.
- W3121073486 crossrefType "journal-article" @default.
- W3121073486 hasAuthorship W3121073486A5017159626 @default.
- W3121073486 hasAuthorship W3121073486A5038009031 @default.
- W3121073486 hasAuthorship W3121073486A5042149117 @default.
- W3121073486 hasAuthorship W3121073486A5062847775 @default.
- W3121073486 hasAuthorship W3121073486A5089366807 @default.
- W3121073486 hasBestOaLocation W31210734861 @default.
- W3121073486 hasConcept C176947019 @default.
- W3121073486 hasConcept C2777050379 @default.
- W3121073486 hasConcept C2777427914 @default.
- W3121073486 hasConcept C2777637488 @default.
- W3121073486 hasConcept C2778512257 @default.
- W3121073486 hasConcept C2779259085 @default.
- W3121073486 hasConcept C2779375183 @default.
- W3121073486 hasConcept C2779631663 @default.
- W3121073486 hasConcept C2780416669 @default.
- W3121073486 hasConcept C2780950330 @default.
- W3121073486 hasConcept C4937899 @default.
- W3121073486 hasConcept C501593827 @default.
- W3121073486 hasConcept C523546767 @default.
- W3121073486 hasConcept C54355233 @default.
- W3121073486 hasConcept C71924100 @default.
- W3121073486 hasConcept C86803240 @default.
- W3121073486 hasConcept C89423630 @default.
- W3121073486 hasConcept C94665300 @default.
- W3121073486 hasConceptScore W3121073486C176947019 @default.
- W3121073486 hasConceptScore W3121073486C2777050379 @default.
- W3121073486 hasConceptScore W3121073486C2777427914 @default.
- W3121073486 hasConceptScore W3121073486C2777637488 @default.
- W3121073486 hasConceptScore W3121073486C2778512257 @default.
- W3121073486 hasConceptScore W3121073486C2779259085 @default.
- W3121073486 hasConceptScore W3121073486C2779375183 @default.
- W3121073486 hasConceptScore W3121073486C2779631663 @default.
- W3121073486 hasConceptScore W3121073486C2780416669 @default.
- W3121073486 hasConceptScore W3121073486C2780950330 @default.
- W3121073486 hasConceptScore W3121073486C4937899 @default.
- W3121073486 hasConceptScore W3121073486C501593827 @default.
- W3121073486 hasConceptScore W3121073486C523546767 @default.
- W3121073486 hasConceptScore W3121073486C54355233 @default.
- W3121073486 hasConceptScore W3121073486C71924100 @default.
- W3121073486 hasConceptScore W3121073486C86803240 @default.
- W3121073486 hasConceptScore W3121073486C89423630 @default.
- W3121073486 hasConceptScore W3121073486C94665300 @default.
- W3121073486 hasIssue "Supplement_1" @default.
- W3121073486 hasLocation W31210734861 @default.
- W3121073486 hasLocation W31210734862 @default.
- W3121073486 hasLocation W31210734863 @default.
- W3121073486 hasOpenAccess W3121073486 @default.
- W3121073486 hasPrimaryLocation W31210734861 @default.
- W3121073486 hasRelatedWork W2138307447 @default.
- W3121073486 hasRelatedWork W2158629630 @default.
- W3121073486 hasRelatedWork W2890378160 @default.
- W3121073486 hasRelatedWork W2894903144 @default.
- W3121073486 hasRelatedWork W2981506776 @default.
- W3121073486 hasRelatedWork W3023495240 @default.
- W3121073486 hasRelatedWork W3121073486 @default.
- W3121073486 hasRelatedWork W3126766207 @default.
- W3121073486 hasRelatedWork W3129162067 @default.
- W3121073486 hasRelatedWork W3196287570 @default.
- W3121073486 hasVolume "7" @default.
- W3121073486 isParatext "false" @default.
- W3121073486 isRetracted "false" @default.
- W3121073486 magId "3121073486" @default.
- W3121073486 workType "article" @default.